"We have had the great pleasure to work with Dr. Furman at Paracelsus on ENDECE’s lead oncolytic candidate, NDC-1308, and now consider her to be our “go to” person for toxicology..."
Endece
Dr. James Yarger, CEO

Company Profile

The comprehensive nonclinical testing program required to support clinical development and ultimate registration of a novel therapeutic involves years of work and many different types of studies. This nonclinical program - which begins prior to initiation of clinical trials and often continues after a drug is approved for marketing - is an essential component of the pharmaceutical R&D process and represents a considerable financial investment to the innovator.

Proficient design and support of nonclinical testing programs requires a customized and integrative strategy that is relevant to the intended clinical indication and acceptable to global health authorities.

Paracelsus can help your organization successfully meet this challenge by offering a range of professional consulting services.  Discipline-specific expertise in key areas such as toxicology, veterinary pathology, pharmacology, pharmacokinetics, and regulatory affairs (strategic and operational) is available to Paracelsus clients through highly knowledgeable and experienced professionals.